Wrap Text
US$2,035,000,000 and ZAR 7,330,000,000
Acquisition Finance Facilities
ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
Registration number 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
("Aspen" or "the Company")
US$2,035,000,000 and ZAR 7,330,000,000
Acquisition Finance Facilities
Aspen is pleased to confirm that, following a very successful senior syndication of the US$2,035,000,000
acquisition finance facilities for Aspen Global Incorporated (“AGI” or the “Borrower”) a 100% owned
subsidiary of Aspen, Bank of America Merrill Lynch and The Standard Bank of South Africa Limited (“SBSA”)
(together the “Initial Mandated Lead Arrangers and Bookrunners”) have now launched the transaction into
general syndication.
Prior to the launch of general syndication, and as a result of a very successful senior syndication, those banks
that committed as sub-underwriters had their allocations scaled back to the requested final hold commitments.
During senior syndication Absa Bank Limited, BNP Paribas, Nedbank Limited, The Royal Bank of Scotland
plc, Standard Chartered Bank committed as Non-Active Bookrunners and Mandated Lead Arrangers;
FirstRand Bank Limited as a Senior Lead Arranger; and Investec Bank Limited, National Australia Bank
Limited and The Bank of Tokyo-Mitsubishi UFJ Limited as Senior Arrangers.
The Facilities which were partially underwritten by the Initial Mandated Lead Arrangers will be used to (i)
support AGI‘s previosuly announced potential acquisition of product portfolios from Merck & Co,
GlaxoSmithKline as well as two other pre-identified acquisitions; and (ii) refinance all of AGI’s existing term
bank debt.
The Facilities
The summary terms of the Facilities are as follows:
Initial Currency of
Borrower Facility Amount Tenor
Margin Commitment
Aspen
Term Loan
Global US$730,000,000 3 years 240 bps USD
Facility A
Incorporated
Amortising
Term Loan US$730,000,000 5 years 250 bps USD
Facility B
Term Loan
US$237,500,000 3 years 240 bps USD
Facility C1
Amortising
Term Loan US$237,500,000 5 years 250 bps USD
Facility C2
With respect to the syndication of the ZAR 7,330,000,000 facilities for Pharmacare Limited (a 100% owned
subsidiary of Aspen) and Aspen, it is confirmed that commitments have been received and allocated on the
ZAR funding, with significant support from the local ZAR Banking and Institutional market. The ZAR facilities
were 132% oversubscribed resulting in scale back of the ZAR commitments. The oversubscription and
subsequent scale back resulted in the ZAR sub-underwriting banks committing incremental liquidity to the
USD denominated facilities.
For any further enquiries, please contact:
Hymie Shapiro
Group Financial Executive
Aspen Pharmacare Holdings Limited
Tel: +27 11 239 6124
Email: shapiroh@aspenpharma.com
Woodmead
13 September 2013
Sponsor: Investec Bank Limited
Date: 13/09/2013 04:30:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
